LuCED® Lung Test
VisionGate’s LuCED lung test is being developed for future availability in the company’s state-of-the-art CLIA laboratory, the VisionGate Biosignature Laboratories (VBL).
When physicians begin prescribing the LuCED test, patients will be asked to provide a sputum sample (phlegm from a deep cough) over a three-day collection period using a take-home test kit that includes pre-paid shipping to VBL. Once the specimen arrives at VBL, it will be processed on our proprietary Cell-CT™ platform, a component of the LuCED test.
The Cell-CT platform produces high-resolution 3D images of individual cells contained in the sputum and measures hundreds of critical disease indicators in each cell. Together, these produce a cell classification that aids in the prediction of disease. The LuCED lung test classifies the cells as normal or abnormal. Our licensed cytologist screens the images and then our pathologist reviews the images and signs out the case as normal or abnormal. Those results are sent to the ordering physician.